The safety, tolerability, and pharmacokinetics(PK)/pharmacodynamics (PD) of DA-3031 (PEG-G-CSF) following a single dose delivered by subcutaneous (SC) injection were investigated in healthy volunteers. PK/PD of filgrastim (Dong-A) following repeated dose delivered by SC injection were investigated in healthy volunteers. PK/PD from a single dose of DA-3031 and repeated dose of filgrastim (Dong-A) were compared.

Inclusion Criteria:

• Healthy males subjects, 20-40 years inclusive
• weight 60-75 kg inclusive and Ideal Body Weight (IBW) between -15% and +15% inclusive
• Written informed consent given
• Willing and able to comply with the requirements of the protocol

Exclusion Criteria:

• Hypersensitivity to drugs(aspirin, antibiotics and so on)
• History or presence of any clinically significant liver or kidney disease, gastrointestinal, cardiovascular, respiratory, endocrinal, musculoskeletal, neurologic/psychiatric, hematological, oncological pathology
• Have a history of drug abuse, or show positive for drug abuse at urine screening
• Have participated in another clinical study within 2 months prior to entering inth the study
• Have been persistently drinking alcohol or can not stop drinking alcohol during the study
• Smokers whose average smoke for last 3 months is more than 10 cigarettes/day
• Are considered ineligible by the investigator due to clinical laboratory results or any other relevant reasons